9439 related articles for article (PubMed ID: 19068467)
1. [Examination of different factors influencing the vascularization of human cutaneous melanoma].
Kiss J
Magy Onkol; 2008 Dec; 52(4):385-9. PubMed ID: 19068467
[TBL] [Abstract][Full Text] [Related]
2. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma.
Kiss J; Tímár J; Somlai B; Gilde K; Fejôs Z; Gaudi I; Ladányi A
Pathol Oncol Res; 2007; 13(1):21-31. PubMed ID: 17387385
[TBL] [Abstract][Full Text] [Related]
3. Hyperforin acts as an angiogenesis inhibitor.
Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
[TBL] [Abstract][Full Text] [Related]
4. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.
Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC
Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844
[TBL] [Abstract][Full Text] [Related]
6. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
Martínez-Poveda B; Quesada AR; Medina MA
Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
[TBL] [Abstract][Full Text] [Related]
7. Hyperforin: more than an antidepressant bioactive compound?
Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
[TBL] [Abstract][Full Text] [Related]
8. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent.
Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A
Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175
[TBL] [Abstract][Full Text] [Related]
11. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
[TBL] [Abstract][Full Text] [Related]
12. Hyperforin, a new lead compound against the progression of cancer and leukemia?
Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
[TBL] [Abstract][Full Text] [Related]
14. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
Straume O; Akslen LA
Am J Pathol; 2001 Jul; 159(1):223-35. PubMed ID: 11438469
[TBL] [Abstract][Full Text] [Related]
15. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
Maniotis AJ; Folberg R; Hess A; Seftor EA; Gardner LM; Pe'er J; Trent JM; Meltzer PS; Hendrix MJ
Am J Pathol; 1999 Sep; 155(3):739-52. PubMed ID: 10487832
[TBL] [Abstract][Full Text] [Related]
16. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases.
Toivonen P; Mäkitie T; Kujala E; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):1-6. PubMed ID: 14691146
[TBL] [Abstract][Full Text] [Related]
17. The changes of angiogenesis and immune cell infiltration in the intra- and peri-tumoral melanoma microenvironment.
Zidlik V; Brychtova S; Uvirova M; Ziak D; Dvorackova J
Int J Mol Sci; 2015 Apr; 16(4):7876-89. PubMed ID: 25913374
[TBL] [Abstract][Full Text] [Related]
18. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.
Quiney C; Billard C; Mirshahi P; Fourneron JD; Kolb JP
Leukemia; 2006 Apr; 20(4):583-9. PubMed ID: 16467866
[TBL] [Abstract][Full Text] [Related]
19. In vitro antimalarial activity of hyperforin, a prenylated acylphloroglucinol. A structure-activity study.
Verotta L; Appendino G; Bombardelli E; Brun R
Bioorg Med Chem Lett; 2007 Mar; 17(6):1544-8. PubMed ID: 17234416
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic insights into the antileukemic activity of hyperforin.
Billard C; Merhi F; Bauvois B
Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
